Get the Stockscreener App
2.63
1.15%
0.03
After Hours:
2.66
0.03
+1.14%
Context Therapeutics Inc stock is traded at $2.63, with a volume of 832.91K.
It is up +1.15% in the last 24 hours and up +16.37% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$2.60
Open:
$2.61
24h Volume:
832.91K
Relative Volume:
0.98
Market Cap:
$241.64M
Revenue:
-
Net Income/Loss:
$-36.12M
P/E Ratio:
-6.8418
EPS:
-0.3844
Net Cash Flow:
$-28.42M
1W Performance:
+21.20%
1M Performance:
+16.37%
6M Performance:
+132.74%
1Y Performance:
+279.56%
1-Day Range:
$2.525
$2.65
1-Week Range:
$2.15
$2.65
52-Week Range:
$0.49
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
2.63 | 238.89M | 0 | -36.12M | -28.42M | -0.3844 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Context Therapeutics (CNTX) Surges Over 8% Amid Renewed Buying Interest Above Key SupportSign of Weakness - Newser
CNTX Q1 2026 Earnings: Context Therapeutics Beats EPS Estimates with Narrower-Than-Expected LossGuidance Revision Trend - Newser
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
CNTX News | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Context Therapeutics Decline Means Insider Profits Down To US$237k - simplywall.st
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
Why Is Context Therapeutics Inc. (CNTX) Stock Down Today? - Meyka
Why Is Context Therapeutics Inc. (CNTX) Stock Up Today? - Meyka
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal - Moomoo
Context Therapeutics Secures Full Rights to CT-202 from BioAtla with License Buyout, Phase 1 Trial Planned for Q3 2026 - Minichart
Context Therapeutics Secures Full Rights to Antibody Assets - TipRanks
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free - TradingView
Context Therapeutics enters into license agreement amendment with BioAtla for CT-202 - marketscreener.com
Context Therapeutics Inc. Announces Amendment to License Agreement for CT-202, Securing Full Economic Rights - Quiver Quantitative
Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license - Stock Titan
Context Therapeutics Enters into License Agreement Amendment with BioAtla - marketscreener.com
Context Therapeutics Advances Cancer Drug Pipeline Toward Data Readouts - MyChesCo
Context Therapeutics (CNTX) Slips -6.87%, Testing $2.06 Support 2026-05-15Fast Rising Picks - Newser
Context Therapeutics (CNTX) Crushes Q1 2026 Estimates — EPS $-0.09 Tops ViewsSocial Buy Zones - Newser
Context Therapeutics (CNTX) joint filing shows 2.44% ownership by Great Point Partners - Stock Titan
Blue Owl Capital Holdings (CNTX) Discloses 5.54% Ownership in Context Therapeutics - Stock Titan
Octagon, Master Fund, Ting Jia file 5.25M-share holding in CNTX (5.7%) - Stock Titan
Avidity entities hold 8.7% of Context Therapeutics (NASDAQ: CNTX) - Stock Titan
Lifesci Capital Issues Positive Estimate for CNTX Earnings - MarketBeat
HC Wainwright Issues Optimistic Outlook for CNTX Earnings - MarketBeat
LifeSci Capital Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Soleus entities (CNTX) report 6.96M shares, 7.6% stake disclosed - Stock Titan
A Quick Look at Today's Ratings for Context Therapeutics(CNTX.US), With a Forecast Between $5 to $7 - Moomoo
Piper Sandler Sticks to Its Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail
CNTX Context Therapeutics Q4 loss widens, misses estimates by 29%; shares drop 3.3% on earnings disappointment.Outlook Update - Newser
What makes Context Therapeutics (CNTX) a compelling holding for the long term (-3.32%) 2026-05-08Bearish Pattern Stocks - Newser
Context Therapeutics Inc. (CNTX) Eps Diluted (TTM) - Zacks Investment Research
Cancer drug developer maps 3 trial milestones as cash lasts to 2027 - Stock Titan
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results - GlobeNewswire
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Context Therapeutics (NASDAQ: CNTX) widens Q1 2026 loss as R&D climbs - Stock Titan
CNTX Earnings History & Surprises | EPS & Revenue Results | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Context Therapeutics settles governance lawsuit with mootness fee - TipRanks
Context Therapeutics (NASDAQ: CNTX) ends charter suit with $850K mootness fee - Stock Titan
H.C. Wainwright Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Context Therapeutics (CNTX) to Release Quarterly Earnings on Wednesday - MarketBeat
[ARS] Context Therapeutics Inc. SEC Filing - Stock Titan
Context Therapeutics (NASDAQ: CNTX) plans vote on board slate and 300M-share authorization - Stock Titan
Positive Signs As Multiple Insiders Buy Context Therapeutics Stock - Yahoo Finance
Context Therapeutics (CNTX) price target increased by 13.33% to 5.78 - MSN
Is Context Therapeutics (CNTX) stock a good candidate for diversification | Q4 2025: EPS Misses EstimatesMarket Risk - Xã Thanh Hà
CNTX (Context Therapeutics Inc.) shares rise 6.11 percent even as Q4 2025 EPS lands below consensus analyst estimates.Trending Volume Leaders - Xã Thanh Hà
Is Context Therapeutics (CNTX) stock forming lower lows | Q4 2025: EPS Misses EstimatesPayout Ratio - Xã Vĩnh Công
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Piper Sandler Reaffirms Their Buy Rating on Context Therapeutics (CNTX) - The Globe and Mail
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):